On November 1, 2018 Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) therapies for cancer, reported that it will present data supporting its allogeneic pipeline program during the 60th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting & Exposition, taking place December 1-4 at the San Diego Convention Center (Press release, Allogene, NOV 1, 2018, View Source [SID1234530652]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"ASH is the first significant medical meeting where we will present data on programs led by Allogene," said David Chang, M.D., Ph.D., President, Chief Executive Officer and Co-Founder of Allogene. "Our teams have spent years doing extensive preclinical research across our pipeline and the development of UCART19 with our partner Servier continues to provide insights that inform and accelerate the strategy for ALLO-501 (anti-CD19) in non-Hodgkin lymphoma. This work is important as we look ahead to our first Investigational New Drug (IND) applications for ALLO-501 and ALLO-715 (anti-BCMA) in multiple myeloma in 2019."
The ASH (Free ASH Whitepaper) abstracts are now available at www.hematology.org. The oral and poster presentations will include additional data not available in the abstracts. Details are as follows.
Allogene Oral Presentation
Session: 652. Myeloma: Pathophysiology and Pre-Clinical Studies, excluding Therapy: Development of Novel Immunotherapeutic Approaches in Multiple Myeloma
Abstract #591
Title: ALLO-715, an Allogeneic BCMA CAR T Therapy Possessing an Off-Switch for the Treatment of Multiple Myeloma
Presenter: Cesar Sommer, Ph.D., Allogene Therapeutics
Session Date & Time: Monday, December 3, 7:00-8:30 a.m. PT
Presentation Time: 7:30 a.m. PT
Location: Ballroom 20D
Allogene Poster Presentation
Session: 703. Adoptive Immunotherapy: Poster II
Abstract #3335
Title: ALLO-819, an Allogeneic Flt3 CAR T Therapy Possessing an Off-Switch for the Treatment of Acute Myeloid Leukemia
Presenter: Cesar Sommer, Ph.D., Allogene Therapeutics
Session Date & Time: Sunday, December 2, 6:00-8:00 p.m. PT
Location: Hall GH
Oral Presentation in Collaboration with Development Partner
UCART19, sponsored by Servier1, is in Phase 1 development for the treatment of relapsed/refractory acute lymphoblastic leukemia (ALL).
Session: 612. Acute Lymphoblastic Leukemia: Clinical
Abstract #896
Title: Preliminary Data on Safety, Cellular Kinetics and Anti-Leukemic Activity of UCART19, an Allogeneic Anti-CD19 CAR T-Cell Product, in a Pool of Adult and Pediatric Patients with High-Risk CD19+ Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
Presenter: Reuben Benjamin, MBBS, MRCP, FRCPath, Ph.D., King’s College Hospital, London
Session Date & Time: Monday, December 3, 4:30-6:00 p.m. PT
Presentation time: 4:45 p.m. PT
Location: Room 6A
UCART19, ALLO-715 and ALLO-819 utilize the TALEN gene-editing technology pioneered and owned by Cellectis.
UCART19, initially developed by Cellectis, is now exclusively licensed to Servier and is under joint clinical development between Servier and Allogene.
ALLO-715 and ALLO-819 were progressed under a joint research collaboration with Cellectis, and are directed at targets that were licensed exclusively from Cellectis. Allogene holds the exclusive global development and commercial rights for these product candidates.